Pharmacovigilance can be defined as a set of practices aiming at the detection, understanding and assessment of risks related to the use of drugs in a population, and the prevention of consequential adverse effects. In a narrower sense, the term refers exclusively to postmarket surveillance. This paper briefly outlines how pharmacovigilance has come to play a central role in the regulation of novel pharmaceuticals. However, the focus of the text is on mechanisms emerging in an experimental drug scene that aim at dealing with the risks posed by `designer drugs' newly introduced to the black market. This discussion of pharmacovigilance and `post-black market surveillance' is situated in the broader context of the more recent dissemination of vigilance as a key element of government in a world too complex for legal and disciplinary measures alone.
Aagard, Lise, Birthe Soendergaard, Elin Andersen, Jens Peter Kampmann & Ebba Holme Hansen (2007) `Creating Knowledge about Adverse Drug Reactions: A Critical Analysis of the Danish Reporting System from 1968 to 2005', Social Science & Medicine65: 1296-1309.
2.
Abraham, John (2002) `Transnational Industrial Power, the Medical Profession and the Regulatory State: Adverse Drug Reactions and the Crisis over the Safety of Halcion in the Netherlands and the UK', Social Science & Medicine55: 1671-90.
3.
Abraham, John (2007) `Drug Trials and Evidence Bases in International Regulatory Context', BioSocieties2: 41-56.
4.
Abraham, John & Courtney Davis (2005) `A Comparative Analysis of Drug Safety Withdrawals in the UK and the US (1971-1992): Implications for Current Regulatory Thinking and Policy', Social Science & Medicine61: 881-92.
5.
Abraham, John & Courtney Davis (2006) `Testing Times: The Emergence of the Practolol Disaster and its Challenge to British Drug Regulation in the Modern Period', Social History of Medicine19(1): 127-47.
6.
Abraham, John & Graham Lewis (1999) `Harmonising and Competing for Medicines Regulation: How Healthy are the European Union's Systems of Drug Approval?', Social Science & Medicine48: 1655-67.
7.
Amendt, Günter (2008) Die Legende vom LSD (Frankfurt/M. : Zweitausendeins).
8.
Angell, Marcia (2006) `Your Dangerous Drugstore', New York Review of Books53(10): 38-40.
9.
Arruñada, Benito (2004) `Quality Safeguards and Regulation of Online Pharmacies' , Health Economics13(4): 329-44.
10.
Barbot, Janine (2006) `How to Build an "Active" Patient? The Work of AIDS Associations in France', Social Science & Medicine62: 538-51.
11.
Beck, Ulrich (1992) Risk Society: Towards a New Modernity ( London: Sage Publications).
12.
Boal, Mark (2002) `A Journey into the Designer Drug Underground' , Rolling Stone (888) (31 January).
13.
Boyer, Edward, M. Shannon & P. Hibberd (2001) `Web Sites with Misinformation about Illicit Drugs' , New England Journal of Medicine345(6): 469-71.
14.
Callon, Michel & Vololona Rabeharisoa (2003) `Research "in the Wild" and the Shaping of New Social Identities', Technology in Society25: 193-204.
15.
CBS Broadcasting (2003) `Debate On Recreational Drug Web Sites', available at <www.cbsnews.com/stories/2003/01/27/eveningnews/main538154.shtml> ; (accessed 27 September 2007).
16.
Ceccoli, Stephen (2002) `Divergent Paths to Drug Regulation in the United States and the United Kingdom', Journal of Policy History14(2): 135-69.
17.
Clark, D.W., E. Donnelly, D.M. Coulter, R.L. Roberts & M.A. Kennedy (2004) `Linking Pharmacovigilance with Pharmacogenetics' , Drug Safety27(15): 1171-84.
18.
Collier, Stephen, Andrew Lakoff & Paul Rabinow (2004) `Biosecurity: Towards an Anthropology of the Contemporary' , Anthropology Today20(5): 3-7.
19.
Cousto, Hans (2002) `Drug-checking in Europa: Die Situation in verschiedenen äLändern im Vergleich', available at <www.eve-rave.net/abfahrer/download/eve-rave/dc112.pdf> ; (accessed 23 September 2007).
20.
Daemmrich, Arthur (2004) Pharmacopolitics: Drug Regulation in the United States and Germany (Chapel Hill, NC: University of North Carolina Press).
21.
Davis, Erik (2004) `Don't Get High Without It: The Vaults of Erowid Supplies the Ultimate Trip Buddy: Information', LA Weekly (30 April - 6 May).
22.
Dillon, Michael & Luis Lobo-Guerrero (2008) `Biopolitics of Security in the 21st Century: An Introduction', Review of International Studies34: 265-92.
23.
Dumit, Joseph (2004) Picturing Personhood: Brain Scans and Biomedical Identity (Princeton, NJ: Princeton University Press).
24.
Dunn, Elizabeth (2004) `Standards and Person-making in East Central Europe' , in Stephen Collier & Aihwa Ong (eds), Global Assemblages: Technology, Politics, and Ethics as Anthropological Problems (London : Blackwell): 173-93.
25.
Edmond, Andrew (1997) `Pioneers of the Virtual Underground. A History of our Culture', available at <www.erowid.org/psychoactives/history/references/other/1997_edmond_resproject_1.shtml> (accessed 27 March 2005).
26.
Eisner, Bruce (1989) Ecstasy: The MDMA Story (Berkeley, CA: Ronin Publishing).
27.
Engel, Rolf, R. Grohmann, E. Rüther & H. Hippius (2004) `Research Methods in Drug Surveillance', Pharmacopsychiatry37 (Suppl 1): S12-S15.
28.
Epstein, Steven (1996) Impure Science: AIDS, Activism, and the Politics of Knowledge (Berkeley, CA: University of California Press).
29.
Erowid (2001) `Second Reported 2C-T-7 Death', available at <www.erowid.org/chemicals/2ct7/2ct7_death2.shtml> ; (accessed 26 September 2007).
Erowid (2007) `2C-T-7 Dosage', available at <www.erowid.org/chemicals/2ct7/2ct7_dose.shtml> ; (accessed 20 March 2007).
32.
Erowid, Earth & Fire Erowid (2006) `The Value of Experience: Erowid's Collection of First-person Psychoactive Reports', Erowid Extracts10 (June): 14-19. Available at <http://www.erowid.org/experiences/exp_info3.shtml> ; (accessed 20 April 2009).
33.
Erowid, Fire (2005) `Erowid: 10 Years of History', Erowid Extracts8 (June): 12-14.
34.
Fontanarosa, Phil, Rennie Drummond & Catherine DeAngelis (2004) `Postmarketing Surveillance - Lack of Vigilance, Lack of Trust', Journal of the American Medical Association292(21): 2647-50.
35.
Foresight (2005) `Drugs Futures 2025?', Foresight (London: Office of Science and Technology).
36.
Foucault, Michel (1977) Discipline and Punish: The Birth of the Prison (New York: Vintage Books).
37.
Foucault, Michel (1988) `Technologies of the Self', in Luther Martin, Huck Gutman & Patrick Hutton (eds), Technologies of the Self: A Seminar with Michel Foucault ( Amherst, MA: University of Massachusetts Press): 16-49.
38.
Foucault, Michel (2007) Security, Territory and Population: Lectures at the Collège de France, 1977-78 (Houndmills, Hants: Palgrave Macmillan).
39.
Goetz, Thomas (2008) `Practicing Patients', New York Times (23 March).
40.
Graham, David (2004) `Testimony of David J. Graham, MD, MPH', available at <www.senate.gov/~finance/hearings/testimony/2004test/111804dgtest.pdf> ; (accessed 7 September 2007).
41.
Grootheest, Kees van (2003) `The Dawn of Pharmacovigilance: An Historical Perspective' , International Journal of Pharmaceutical Medicine17(5/6): 195-200.
42.
Halpern, John & Harrison Pope (2001) `Hallucinogens on the Internet: A Vast New Source of Underground Drug Information', American Journal of Psychiatry158: 481-83.
43.
Harris, Gardiner (2004) `At F.D.A., Strong Drug Ties and Less Monitoring' , New York Times (6 December).
44.
Harris, Gardiner (2005) `F.D.A. Responds to Criticism With New Caution' , New York Times (6 August).
45.
Harris, Gardiner (2006) `Study Condemns F.D.A.'s Handling of Drug Safety' , New York Times (23 September).
46.
Heywood, James (2008) `Does It Work? Lithium and ALS', available at <blog.patientslikeme.com/2008/02/14/does-it-work-studying-lithium-treatment-for-als/> ; (accessed 7 March 2008).
47.
Hilts, Philip (2003) Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation (New York: Alfred A. Knopf).
48.
House of Commons Health Committee (2005) The Influence of the Pharmaceutical Industry: Fourth Report of Session 2004-05 (London: The Stationery Office Limited).
49.
Jenkins, Philip (1999) Synthetic Panics: The Symbolic Politics of Designer Drugs (New York: New York University Press).
50.
Jensen, Michael (2007) `Authority 3.0: Friend or Foe to Scholars?'Journal of Scholarly Publishing (October): 297-307.
51.
Lampton, L. (2004) `Vioxx, Pharmacovigilance, Flu Vaccine , and the "Prepared Mind"', Journal Mississippi State Medical Association45(11): 333-35.
52.
Langlitz, Nicolas (2006) `Tripping in Solitude: Introducing Honza Samotar by Way of John Lilly', in Katrin Solhdju (ed.), Introspective Self-rapports: Shaping Ethical and Aesthetic Concepts, 1850-2006 (Preprint 322) (Berlin: Max-Planck-Institut für Wissenschaftsgeschichte): 81-92.
53.
Langlitz, Nicolas (2009) `The Persistence of the Subjective in Cognitive Neuroscience: Observations of Contemporary Hallucinogen Research', History of the Human Sciences. (In Press)
54.
Latour, Bruno (2001) `What Rules of Method for the New Socio-scientific Experiments?' in Experimental Cultures: Configurations between Science, Art, and Technology, 1830-1950 (Preprint 213) ( Berlin: Max-Planck-Institut für Wissenschaftsgeschichte ): 123-35.
55.
Lemke, Thomas (2007) Gouvernementalität und Biopolitik ( Wiesbaden: VS Verlag für Sozialwissenschaften).
Luhmann, Niklas (1993) Risk: A Sociological Theory ( New York: Walter de Gruyter).
58.
Luhmann, Niklas (1998) Observations on Modernity ( Stanford, CA: Stanford University Press).
59.
Luhmann, Niklas (2000) Vertrauen (Stuttgart: Lucius & Lucius).
60.
Maehle, Andreas-Holger (1995), `Selbstversuche und subjektive Erfahrung in der Opiumforschung des 18. Jahrhunderts', Würzburger Medizinhistorische Mitteilungen13: 294.
61.
Mann, Ronald & Elizabeth Andrews (eds) (2002) Pharmacovigilance (Chichester, Sussex: John Wiley & Sons ).
62.
Marks, Harry (1997) The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990 (Cambridge: Cambridge University Press).
63.
McGoey, Linsey (2007) `On the Will to Ignorance in Bureaucracy', Economy and Society36(2): 212-35.
64.
Medawar, Charles, Andrew Herxheimer, Andrew Bell & Shelley Jofre (2002) `Paroxetine, Panorama and User Reporting of ADRs: Consumer Intelligence Matters in Clinical Practice and Post-marketing Drug Surveillance', International Journal of Risk & Safety in Medicine15: 161-69.
65.
Metzinger, Thomas (1996) `Hirnforschung, Neurotechnologie, Bewu§tseinskultur. Medizinethische, Anthropologische und Sozialphilosophische Fragen der Zukunft' , in Gert Kaiser, Johannes Siegrist, Eva Rosenfeld & Katharina Wetzel-Vandai (eds), Die Zukunft der Medizin. Neue Wege zur Gesundheit? (Frankfurt/M. : Campus): 301-12.
66.
Metzinger, Thomas (2000) `Introduction: Consciousness Research at the End of the Twentieth Century', in Thomas Metzinger (ed), Neural Correlates of Consciousness: Empirical and Conceptual Questions (Cambridge, MA: MIT Press): 1-16.
67.
Murguía, Edward, Melissa Tackett-Gibson & Rachel Willard (2006) `Club Drugs, Online Communities, and Harm Reduction Websites on the Internet', in E. Murguía, M. Tackett-Gibson & A. Lessem (eds), Real Drugs in a Virtual World: Drug Discourse and Community Online ( Lanham, MD: Lexington Books): 5-22.
68.
Murple (2001) `Sulfurous Samadhi: An Investigation of 2C-T-2 & 2C-T-7', available at <www.erowid.org/chemicals/2ct7/article1/article1.shtml> ; (accessed 27 July 2005).
69.
Platoni, Kara (2002) `2C-T-7's Bad Trip', East Bay Express000: 000-000.
70.
Porter, Theodore (1992) `Quantification and the Accounting Ideal in Science' , Social Studies of Science22(4): 633-51.
71.
Rabinow, Paul (2004) `Assembling Ethics in an Ecology of Ignorance' , available at <http://openwetware.org/images/7/7a/SB1.0_Rabinow.pdf> ; (accessed 20 March 2007).
72.
Rabinow, Paul (2008) Marking Time: On the Anthropology of the Contemporary (Princeton, NJ: Princeton University Press).
73.
Rose, Nikolas (1999) Powers of Freedom. Reframing Political Thought (Cambridge: Cambridge University Press).
74.
Routledge, Philip (1998) `150 Years of Pharmacovigilance', Lancet351: 1200-01.
75.
Schaffer, Simon (1992) `Self Evidence', Critical Inquiry18(2): 327-62.
76.
Schiavone, Sergio (2002) `[Illicit market of controlled drugs in Italy: new drugs and trends]', Annali dell'Istituto superiore di sanità38(3): 315-18.
77.
Shapin, Steven (1999) `The House of Experiment in Seventeenth-century England', in Mario Biagioli (ed.), The Science Studies Reader (New York: Routledge): 479-504.
78.
Shulgin, Alexander & Ann Shulgin (1991) PIHKAL: A Chemical Love Story (Berkeley, CA: Transform Press ).
79.
Shulgin, Alexander & Ann Shulgin (1997) TIHKAL: The Continuation (Berkeley, CA: Transform Press ).
80.
Sloterdijk, Peter (1996) Selbstversuch: Ein Gespräch mit Carlos Oliveira (München: Carl Hanser Verlag).
81.
St. George, B.N., J.R. Emmanuel & K.L. Middleton (2004) `Overseas-based Online Pharmacies: A Source of Supply for Illicit Drug Users?'Medical Journal of Australia180(3): 118-19.
82.
Szarfman, A., J.M. Tonning & P.M. Doraiswamy (2004) `Pharmacovigilance in the 21st Century: New Systematic Tools for an Old Problem', Pharmacotherapy24(9): 1122-29.
83.
Thyssen, Sylvia & Earth Erowid (2006) `Erowid Presents at the North American Congress of Clinical Toxicology', Erowid Extracts11: 22-23.
84.
Topol, Eric (2004) `Failing the Public Health - Rofecoxib, Merck, and the FDA', New England Journal of Medicine315(17): 1707-09.
85.
Trontell, Anne (2004) `Expecting the Unexpected: Drug Safety, Pharmacovigilance, and the Prepared Mind', New England Journal of Medicine351(14): 1385-87.
86.
Wax, Paul (2002) `Just a Click Away: Recreational Drug Web Sites on the Internet', Pediatrics109 (6 June).
87.
West Midlands Centre for Adverse Drug Reaction Reporting (2007) `The Pharmacovigilance Timeline', available at <http://adr.org.uk/?page_id=94> (accessed 27 September 2007).
88.
Wiktorowicz, Mary (2003) `Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France', Journal of Health Politics, Policy and Law28(4): 615-58.
89.
World Health Organization (2002) `The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products' , World Health Organization, available at <http://whqlibdoc.who.int/hq/2002/a75646.pdf> (accessed 27 September 2007).
